Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke

S. W. Worm; D. A. Kamara; P. Reiss; E. Fontas; S. de Wit; W. El-Sadr; A. d'Arminio Monforte; M. Law; A. Phillips; L. Ryom; F. Dabis; R. Weber; C. Sabin; J. D. Lundgren

doi:10.1093/infdis/jir788

Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke

S. W. Worm
, D. A. Kamara
, P. Reiss
, E. Fontas
, S. de Wit
, W. El-Sadr
, A. d'Arminio Monforte
, M. Law
, A. Phillips
, L. Ryom
, F. Dabis
, R. Weber
, C. Sabin
, J. D. Lundgren

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Concerns have arisen about possible effects of protease inhibitors (PIs) on cardiac conductivity. We found no significant association between current or recent PI exposure and sudden death or nonhemorrhagic stroke (adjusted rate ratio, 1.22; 95% confidence interval, .95-1.57), whereas cumulative exposure to PIs was associated with an increased risk (adjusted rate ratio, 1.06 per year of exposure; 95% confidence interval, 1.01-1.11)

Original language	English
Pages (from-to)	535-539
Journal	Journal of infectious diseases
Volume	205
Issue number	4
DOIs	https://doi.org/10.1093/infdis/jir788
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/infdis/jir788

Cite this

Worm, S. W., Kamara, D. A., Reiss, P., Fontas, E., de Wit, S., El-Sadr, W., d'Arminio Monforte, A., Law, M., Phillips, A., Ryom, L., Dabis, F., Weber, R., Sabin, C., & Lundgren, J. D. (2012). Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke. Journal of infectious diseases, 205(4), 535-539. https://doi.org/10.1093/infdis/jir788

@article{4764c6109ba84afcbe6060a8f5defbdb,

title = "Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke",

abstract = "Concerns have arisen about possible effects of protease inhibitors (PIs) on cardiac conductivity. We found no significant association between current or recent PI exposure and sudden death or nonhemorrhagic stroke (adjusted rate ratio, 1.22; 95\% confidence interval, .95-1.57), whereas cumulative exposure to PIs was associated with an increased risk (adjusted rate ratio, 1.06 per year of exposure; 95\% confidence interval, 1.01-1.11)",

author = "Worm, \{S. W.\} and Kamara, \{D. A.\} and P. Reiss and E. Fontas and \{de Wit\}, S. and W. El-Sadr and \{d'Arminio Monforte\}, A. and M. Law and A. Phillips and L. Ryom and F. Dabis and R. Weber and C. Sabin and Lundgren, \{J. D.\}",

year = "2012",

doi = "10.1093/infdis/jir788",

language = "English",

volume = "205",

pages = "535--539",

journal = "Journal of infectious diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke

AU - Worm, S. W.

AU - Kamara, D. A.

AU - Reiss, P.

AU - Fontas, E.

AU - de Wit, S.

AU - El-Sadr, W.

AU - d'Arminio Monforte, A.

AU - Law, M.

AU - Phillips, A.

AU - Ryom, L.

AU - Dabis, F.

AU - Weber, R.

AU - Sabin, C.

AU - Lundgren, J. D.

PY - 2012

Y1 - 2012

N2 - Concerns have arisen about possible effects of protease inhibitors (PIs) on cardiac conductivity. We found no significant association between current or recent PI exposure and sudden death or nonhemorrhagic stroke (adjusted rate ratio, 1.22; 95% confidence interval, .95-1.57), whereas cumulative exposure to PIs was associated with an increased risk (adjusted rate ratio, 1.06 per year of exposure; 95% confidence interval, 1.01-1.11)

AB - Concerns have arisen about possible effects of protease inhibitors (PIs) on cardiac conductivity. We found no significant association between current or recent PI exposure and sudden death or nonhemorrhagic stroke (adjusted rate ratio, 1.22; 95% confidence interval, .95-1.57), whereas cumulative exposure to PIs was associated with an increased risk (adjusted rate ratio, 1.06 per year of exposure; 95% confidence interval, 1.01-1.11)

U2 - 10.1093/infdis/jir788

DO - 10.1093/infdis/jir788

M3 - Article

C2 - 22223855

SN - 0022-1899

VL - 205

SP - 535

EP - 539

JO - Journal of infectious diseases

JF - Journal of infectious diseases

IS - 4

ER -

Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this